Showing results (161-170 of 286) with videos related to
Sort By:
Pageof 29
British Journal of Cancer|September 12, 2018
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006Omid Hamid, Caroline Robert, Antoni Ribas, et al.Frontiers in Oncology|June 7, 2014
Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 LevelsAnna M Leung, Agnes Fermin Lee, Junko Ozao-Choy, et al.Cancer Chemotherapy and Pharmacology|January 7, 2014
Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignanciesDaruka Mahadevan, Gregory Ryan Sutton, Rafael Arteta-Bulos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant MelanomaAntoni Ribas, Adil Daud, Anna C Pavlick, et al.Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.Journal for Immunotherapy of Cancer|March 22, 2019
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanomaGeoffrey T Gibney, Omid Hamid, Jose Lutzky, et al.Investigational New Drugs|February 24, 2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trialAfshin Dowlati, R Donald Harvey, Richard D Carvajal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid TumorsOmid Hamid, Dana B Cardin, F Stephen Hodi, et al.The Journal of Clinical and Aesthetic Dermatology|January 25, 2021
The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric ComorbiditiesRyan Rivera-Oyola, Roselyn Stanger, Graham H Litchman, et al.Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020Paolo A Ascierto, Michael B Atkins, Alexander M Eggermont, et al.Pageof 29